Steve Deitelzweig

642 total citations
22 papers, 494 citations indexed

About

Steve Deitelzweig is a scholar working on Cardiology and Cardiovascular Medicine, Economics and Econometrics and Internal Medicine. According to data from OpenAlex, Steve Deitelzweig has authored 22 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Cardiology and Cardiovascular Medicine, 8 papers in Economics and Econometrics and 6 papers in Internal Medicine. Recurrent topics in Steve Deitelzweig's work include Atrial Fibrillation Management and Outcomes (21 papers), Cardiac Arrhythmias and Treatments (9 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Steve Deitelzweig is often cited by papers focused on Atrial Fibrillation Management and Outcomes (21 papers), Cardiac Arrhythmias and Treatments (9 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Steve Deitelzweig collaborates with scholars based in United States, Germany and United Kingdom. Steve Deitelzweig's co-authors include Jay Lin, Daniel Wiederkehr, Dinara Makenbaeva, Yonghua Jing, John Graham, Alpesh Amin, Xuemei Luo, Kiran Gupta, Jack Mardekian and Allison Keshishian and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and PLoS ONE.

In The Last Decade

Steve Deitelzweig

21 papers receiving 482 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steve Deitelzweig United States 10 456 250 77 70 16 22 494
Annya Stephens-Boal United Kingdom 3 451 1.0× 232 0.9× 85 1.1× 95 1.4× 40 2.5× 9 543
S. K. Rushton-Smith United Kingdom 10 670 1.5× 246 1.0× 61 0.8× 133 1.9× 50 3.1× 14 720
Yukihiro Koretsune Japan 14 393 0.9× 109 0.4× 32 0.4× 56 0.8× 22 1.4× 31 436
Alan John Camm United Kingdom 10 629 1.4× 155 0.6× 60 0.8× 73 1.0× 39 2.4× 15 670
Peter J Svensson Sweden 13 480 1.1× 207 0.8× 26 0.3× 70 1.0× 44 2.8× 19 521
Gheorghe‐Andrei Dan Romania 10 874 1.9× 180 0.7× 93 1.2× 88 1.3× 31 1.9× 16 910
Gloria Kayani United Kingdom 8 461 1.0× 168 0.7× 46 0.6× 106 1.5× 30 1.9× 15 503
Maxim Grymonprez Belgium 12 345 0.8× 96 0.4× 57 0.7× 80 1.1× 31 1.9× 33 406
Martin E W Hemels Netherlands 12 435 1.0× 110 0.4× 53 0.7× 48 0.7× 66 4.1× 63 484
Nick Newton United Kingdom 4 649 1.4× 277 1.1× 115 1.5× 167 2.4× 54 3.4× 6 734

Countries citing papers authored by Steve Deitelzweig

Since Specialization
Citations

This map shows the geographic impact of Steve Deitelzweig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Deitelzweig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Deitelzweig more than expected).

Fields of papers citing papers by Steve Deitelzweig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steve Deitelzweig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Deitelzweig. The network helps show where Steve Deitelzweig may publish in the future.

Co-authorship network of co-authors of Steve Deitelzweig

This figure shows the co-authorship network connecting the top 25 collaborators of Steve Deitelzweig. A scholar is included among the top collaborators of Steve Deitelzweig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steve Deitelzweig. Steve Deitelzweig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Deitelzweig, Steve, Xuemei Luo, Jennifer L. Nguyen, et al.. (2022). Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study. Journal of Thrombosis and Thrombolysis. 53(4). 766–776. 8 indexed citations
2.
Deitelzweig, Steve, Amiee Kang, Cristina Russ, et al.. (2021). Effectiveness and Safety of Apixaban Versus Warfarin in Obese Patients with Nonvalvular Atrial Fibrillation Enrolled in Medicare and Veteran Affairs. The American Journal of Cardiology. 163. 43–49. 7 indexed citations
3.
Deitelzweig, Steve, Allison Keshishian, Amiee Kang, et al.. (2020). Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study. Journal of Clinical Medicine. 9(6). 1633–1633. 27 indexed citations
4.
Lip, Gregory Y.H., Allison Keshishian, Amiee Kang, et al.. (2020). Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. Journal of Internal Medicine. 289(1). 42–52. 36 indexed citations
5.
Deitelzweig, Steve, Allison Keshishian, Xiaoyan Li, et al.. (2018). COMPARISON OF EFFECTIVENESS, SAFETY, AND THE NET CLINICAL OUTCOME BETWEEN DIFFERENT DIRECT ORAL ANTICOAGULANTS IN 162,707 NON-VALVULAR ATRIAL FIBRILLATION PATIENTS TREATED IN US CLINICAL PRACTICE. Journal of the American College of Cardiology. 71(11). A275–A275. 3 indexed citations
6.
7.
Deitelzweig, Steve, Xuemei Luo, Kiran Gupta, et al.. (2018). All-Cause, Stroke/Systemic Embolism–, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants. Clinical and Applied Thrombosis/Hemostasis. 24(4). 602–611. 7 indexed citations
8.
Deitelzweig, Steve, Allison Keshishian, Xiaoyan Li, et al.. (2017). Abstract 16462: Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Among Non-Valvular Atrial Fibrillation Patients: A Propensity Score Matched Analysis of Four Large Databases. Circulation. 1 indexed citations
9.
Li, Xiaoyan, Steve Deitelzweig, Allison Keshishian, et al.. (2017). Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. Thrombosis and Haemostasis. 117(6). 1072–1082. 122 indexed citations
10.
Deitelzweig, Steve, Caroline Farmer, Xuemei Luo, et al.. (2017). Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies. Current Medical Research and Opinion. 33(9). 1583–1594. 24 indexed citations
11.
Deitelzweig, Steve, Xuemei Luo, Kiran Gupta, et al.. (2016). Abstract 17298: Real-world Evaluation of Healthcare Resource Use and Costs of Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Apixaban vs. Warfarin in the US. Circulation. 134. 1 indexed citations
12.
Deitelzweig, Steve, et al.. (2016). 42 Incremental Economic Burden Associated With Major Bleeding among Atrial Fibrillation Patients Treated With Factor Xa Inhibitors. Annals of Emergency Medicine. 68(4). S18–S18. 2 indexed citations
13.
Deitelzweig, Steve, Michael A. Evans, Eric Hillson, et al.. (2015). Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation. Current Medical Research and Opinion. 32(1). 87–94. 8 indexed citations
14.
15.
Deitelzweig, Steve, Amanda Bruno, Augustina Ogbonnaya, et al.. (2015). Abstract 339: Hospitalization Rates and Healthcare Costs Among Non-valvular Atrial Fibrillation Patients Who Were Naïve Users of Novel Oral Anticoagulants. Circulation Cardiovascular Quality and Outcomes. 8(suppl_2).
16.
17.
Deitelzweig, Steve, Alpesh Amin, Yonghua Jing, et al.. (2013). Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks. Cardiology and Therapy. 2(2). 165–170. 7 indexed citations
18.
19.
Deitelzweig, Steve, Alpesh Amin, Yonghua Jing, et al.. (2012). Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. Journal of Medical Economics. 15(4). 776–785. 80 indexed citations
20.
Rosenman, Marc B., Yonghua Jing, Dinara Makenbaeva, et al.. (2012). Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records. Current Medical Research and Opinion. 28(9). 1407–1414. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annya Stephens-Boal Breakdown of academic impact, for papers by S. K. Rushton-Smith Breakdown of academic impact, for papers by Yukihiro Koretsune Breakdown of academic impact, for papers by Alan John Camm Breakdown of academic impact, for papers by Peter J Svensson Breakdown of academic impact, for papers by Gheorghe‐Andrei Dan Breakdown of academic impact, for papers by Gloria Kayani Breakdown of academic impact, for papers by Maxim Grymonprez Breakdown of academic impact, for papers by Martin E W Hemels Breakdown of academic impact, for papers by Nick Newton
Rankless by CCL
2026